Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texting your way to quit smoking: telegram bot tested in heart patients

NCT ID NCT07230249

Disease control Sponsor: ITMO University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether a 6-month program delivered through the Telegram messaging app can help people stop smoking after a heart attack. 142 adult smokers who use Telegram will either get the chatbot support or standard advice. The goal is to see if more people quit with the chatbot's help.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telegram-based behavioral support program
What this could lead to
If it works, this could provide a simple, scalable way to help heart attack survivors quit smoking, reducing their risk of future heart problems.
What could go wrong
This is a small, early-stage trial with only 142 people. The intervention relies on a messaging app, so it may not work for everyone, and results may not apply to non-Telegram users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 142 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent. * Age 18 years or older. * Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI). * Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization. * Regular user of the Telegram messenger application (app installed on a personal smartphone). * Possession of a smartphone with internet access and a valid phone number. * Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up. Exclusion Criteria: * Smoking cessation more than 1 month prior to the index MI hospitalization. * Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages). * Inability to read and understand the Russian language fluently. * Comorbid condition with a life expectancy of less than 1 year. * Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence. * Unwillingness or inability to provide contact details for a close relative for outcome verification.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction (MI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction nicotine dependence Smoking Cessation Tobacco Use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction (MI) Smoking cessation Tobacco use

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Ulyanovsk Oblast, 432000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.